ABSTRACT
In this study, we aimed to evaluate the value of single photon emission computed tomography/computed tomography (SPECT/CT) in patients with differentiated thyroid cancer. Although the utility of radioiodine SPECT/CT imaging is controversial in the clinical management of thyroid cancer patients, SPECT/CT is a valuable method in the staging, risk stratification and follow-up of thyroid cancer. Also, in deciding therapy approach, SPECT/CT seems to be an important modality by helping correct localization of activity foci seen on planar radioiodine scintgraphy. Additionally, it had a further clinical impact on the patient management by influencing referral I-131 treatment and tailoring of the administered radioidodine dose, and/or the addition of surgery or external radiation therapy in the cases of non-avid recurrence-metastatic disease.